🇺🇸 FDA
Pipeline program

DP CD8 TIL

2023000082

Phase 1 mab active

Quick answer

DP CD8 TIL for HNSCC is a Phase 1 program (mab) at Phio Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Phio Pharmaceuticals
Indication
HNSCC
Phase
Phase 1
Modality
mab
Status
active

Clinical trials